Alzheimer disease: Treatment of Alzheimer disease in Down syndrome

Nature Reviews Neurology

Volumn 8, Issue 4, 2012, Pages 182-184

  Costa, Alberto C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ATTENTION; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE MODEL; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXECUTIVE FUNCTION; HUMAN; LIFE EXPECTANCY; MEMORY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

ALZHEIMER DISEASE; DOPAMINE AGENTS; DOWN SYNDROME; EXECUTIVE FUNCTION; HUMANS; MEMANTINE; MEMORY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859610080     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.40     Document Type: Short Survey

References (10)

1. Patterson, D. & Costa, A. C. Down syndrome and genetics - a case of linked histories. Nat. Rev. Genet. 6, 137-147 (2005).
2. Zigman, W. B. & Lott, I. T. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment. Retard. Dev. Disabil. Res. Rev. 13, 237-246 (2007).
3. Mohan, M., Carpenter, P. K. & Bennett, C. Donepezil for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD007178. http://dx.doi.org/10.1002/14651858.CD007178.pub2 (2009).
4. Hanney, M. et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379, 528-536 (2012).
5. Margallo-Lana, M. L. et al. Cognitive decline in Down syndrome. Arch. Neurol. 60, 1024 (2003).
6. Holland, A. J. in Dementia, Aging, and Intellectual Disabilities: A Handbook (eds Janicki, M. P. & Dalton, A. J.) 183-197 (Taylor & Francis, Philadelphia, 1999).
7. Pennington, B. F., Moon, J., Edgin, J., Stedron, J. & Nadel, L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 74, 75-93 (2003).
8. Costa, A. C. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev. Neurosci. 33, 414-427 (2011).
9. Scott-McKean, J. J. & Costa, A. C. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn. Mem. 18, 774-778 (2011).
10. Lockrow, J., Boger, H., Bimonte-Nelson, H. & Granholm, A. C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 221, 610-622 (2010).